BioCentury | Sep 20, 2010
Clinical News

Scancell preclinical data

...In a mouse model of melanoma, Scancell's SCIB1 ImmunoBody vaccine in combination with Homspera from ImmuneRegen BioSciences Inc....
...T lymphocyte (CTL) epitopes from tumor antigens over-expressed by cancer cells. In June, Scancell and ImmuneRegen...
BioCentury | Sep 6, 2010
Company News

ImmuneRegen, U.S. Department of Health and Human Services other news

...preclinical testing. ImmuneRegen will submit the proposal jointly with the University of Rochester (Rochester, N.Y.). ImmuneRegen...
...collaborating with the university's Center for Medical Countermeasures against Radiation to develop Homspera since 2009. ImmuneRegen BioSciences Inc....
BioCentury | Jun 14, 2010
Company News

ImmuneRegen, Scancell deal

...The companies will evaluate using Scancell's ImmunoBody vaccine technologies in combination with ImmuneRegen's preclinical candidate Homspera...
...helper cell and cytotoxic T lymphocyte (CTL) epitopes from tumor antigens over-expressed by cancer cells. ImmuneRegen BioSciences Inc....
BioCentury | May 3, 2010
Company News

ImmuneRegen, NeoStem deal

...NeoStem will evaluate the effect of ImmuneRegen's Homspera on stem cell differentiation when combined with NeoStem's...
...a preclinical analog of the naturally occurring immunomodulator substance P. Financial terms were not disclosed. ImmuneRegen BioSciences Inc....
BioCentury | Jan 4, 2010
Clinical News

ImmuneRegen preclinical data

...start Phase I testing of Homspera plus a yet-to-be determined antigen and indication in 3Q10. ImmuneRegen BioSciences Inc....
BioCentury | Nov 16, 2009
Clinical News

ImmuneRegen preclinical data

...symptoms vs. untreated ferrets. Homspera is an analog of the naturally occurring immunomodulator substance P. ImmuneRegen BioSciences Inc....
BioCentury | Sep 28, 2009
Company News

ImmuneRegen, Azopharma Product Development Group deal

...intent for CRO Azopharma to perform manufacturing, formulation development, preclinical toxicology and pharmacology studies of ImmuneRegen's...
...and for wound healing. Azopharma will receive yet to be determined ImmuneRegen shares and warrants. ImmuneRegen BioSciences Inc....
BioCentury | Aug 10, 2009
Clinical News

ImmuneRegen preclinical data

...associated with the infection. Homspera is an analog of the naturally occurring immunomodulator substance P. ImmuneRegen BioSciences Inc....
BioCentury | May 11, 2009
Company News

ImmuneRegen, University of Pittsburgh deal

...ImmuneRegen acquired from the university full rights to a patent covering the active component of ImmuneRegen's...
...was originally co-owned by the parties. The university is eligible for undisclosed milestones and royalties. ImmuneRegen BioSciences Inc....
BioCentury | May 12, 2008
Company News

ImmuneRegen scientific advisory board update

ImmuneRegen BioSciences Inc. (OTCBB:IRBO), Scottsdale, Ariz. Business: Pulmonary Appointed: Ivan Rich, founder, chairman and CEO of HemoGenix Inc. WIR Staff Pulmonary...
Items per page:
1 - 10 of 24
BioCentury | Sep 20, 2010
Clinical News

Scancell preclinical data

...In a mouse model of melanoma, Scancell's SCIB1 ImmunoBody vaccine in combination with Homspera from ImmuneRegen BioSciences Inc....
...T lymphocyte (CTL) epitopes from tumor antigens over-expressed by cancer cells. In June, Scancell and ImmuneRegen...
BioCentury | Sep 6, 2010
Company News

ImmuneRegen, U.S. Department of Health and Human Services other news

...preclinical testing. ImmuneRegen will submit the proposal jointly with the University of Rochester (Rochester, N.Y.). ImmuneRegen...
...collaborating with the university's Center for Medical Countermeasures against Radiation to develop Homspera since 2009. ImmuneRegen BioSciences Inc....
BioCentury | Jun 14, 2010
Company News

ImmuneRegen, Scancell deal

...The companies will evaluate using Scancell's ImmunoBody vaccine technologies in combination with ImmuneRegen's preclinical candidate Homspera...
...helper cell and cytotoxic T lymphocyte (CTL) epitopes from tumor antigens over-expressed by cancer cells. ImmuneRegen BioSciences Inc....
BioCentury | May 3, 2010
Company News

ImmuneRegen, NeoStem deal

...NeoStem will evaluate the effect of ImmuneRegen's Homspera on stem cell differentiation when combined with NeoStem's...
...a preclinical analog of the naturally occurring immunomodulator substance P. Financial terms were not disclosed. ImmuneRegen BioSciences Inc....
BioCentury | Jan 4, 2010
Clinical News

ImmuneRegen preclinical data

...start Phase I testing of Homspera plus a yet-to-be determined antigen and indication in 3Q10. ImmuneRegen BioSciences Inc....
BioCentury | Nov 16, 2009
Clinical News

ImmuneRegen preclinical data

...symptoms vs. untreated ferrets. Homspera is an analog of the naturally occurring immunomodulator substance P. ImmuneRegen BioSciences Inc....
BioCentury | Sep 28, 2009
Company News

ImmuneRegen, Azopharma Product Development Group deal

...intent for CRO Azopharma to perform manufacturing, formulation development, preclinical toxicology and pharmacology studies of ImmuneRegen's...
...and for wound healing. Azopharma will receive yet to be determined ImmuneRegen shares and warrants. ImmuneRegen BioSciences Inc....
BioCentury | Aug 10, 2009
Clinical News

ImmuneRegen preclinical data

...associated with the infection. Homspera is an analog of the naturally occurring immunomodulator substance P. ImmuneRegen BioSciences Inc....
BioCentury | May 11, 2009
Company News

ImmuneRegen, University of Pittsburgh deal

...ImmuneRegen acquired from the university full rights to a patent covering the active component of ImmuneRegen's...
...was originally co-owned by the parties. The university is eligible for undisclosed milestones and royalties. ImmuneRegen BioSciences Inc....
BioCentury | May 12, 2008
Company News

ImmuneRegen scientific advisory board update

ImmuneRegen BioSciences Inc. (OTCBB:IRBO), Scottsdale, Ariz. Business: Pulmonary Appointed: Ivan Rich, founder, chairman and CEO of HemoGenix Inc. WIR Staff Pulmonary...
Items per page:
1 - 10 of 24